- Home
- OPTN
OPTN
OptiNose Inc.
as 10-04-2024 4:00pm EST
OptiNose Inc is a specialty pharmaceutical company that focuses on the development and commercialization of products for patients treated by ear, nose, and throat, and allergy specialists. Its product includes XHANCE (fluticasone propionate) nasal spray, 93 micrograms, a therapeutic utilizing its proprietary Exhalation Delivery System (EDS) that delivers a topically-acting corticosteroid for the treatment of chronic rhinosinusitis with nasal polyps. The XHANCE is able to deliver medication to the primary site of inflammation high and deep in the nasal passages in regions not adequately reached by intranasal steroids.
| Founded: | 2010 | Country: | United States |
| Employees: | N/A | City: | YARDLEY |
| Market Cap: | 117.6M | IPO Year: | 2017 |
| Target Price: | $4.00 | AVG Volume (30 days): | 516.5K |
| Analyst Decision: | Strong Buy | Number of Analysts: | 2 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.35 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.65 - $2.10 | Next Earning Date: | 11-07-2024 |
| Revenue: | $75,058,000 | Revenue Growth: | 3.91% |
| Revenue Growth (this year): | 24.44% | Revenue Growth (next year): | 49.00% |
Stock Insider Trading Activity of OptiNose Inc. (OPTN)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Krick Anthony J | OPTN | Chief Accounting Officer | Jul 17 '24 | Sell | $1.14 | 6,845 | $7,803.30 | 140,758 | |
| Marino Michael F III | OPTN | Chief Legal Officer & Corp Sec | Jul 17 '24 | Sell | $1.14 | 49,408 | $56,325.12 | 550,464 | |
| Mahmoud Ramy A | OPTN | Chief Executive Officer | Jul 17 '24 | Sell | $1.14 | 111,426 | $127,025.64 | 1,206,978 |
Latest OptiNose Inc. News
OPTN Breaking Stock News: Dive into OPTN Ticker-Specific Updates for Smart Investing
Simply Wall St.
22 days ago
OptiNose (NASDAQ:OPTN) shareholders have endured a 88% loss from investing in the stock five years ago
GlobeNewswire
a month ago
New Peer-Reviewed Data Highlight the Benefits of XHANCE in Chronic Rhinosinusitis Patients with or without Prior Sinus Surgery
GlobeNewswire
a month ago
Optinose to Present at the H.C. Wainwright 26th Annual Global Investment Conference
Simply Wall St.
2 months ago
OptiNose Second Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag
Zacks
2 months ago
OptiNose (OPTN) Reports Q2 Loss, Lags Revenue Estimates
Associated Press Finance
2 months ago
OptiNose: Q2 Earnings Snapshot
GlobeNewswire
2 months ago
Optinose Reports Second Quarter 2024 Financial Results and Recent Operational Highlights
GlobeNewswire
2 months ago
Optinose Announces Reporting Date for Second Quarter 2024 Financial Results
Compare OPTN vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "OPTN OptiNose Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.